Mice with osteopontin deletion remain predisposed to collagen-induced arthritis

Arthritis and Rheumatism

Volumn 50, Issue 2, 2004, Pages 669-671

  Ishii, Taeko ^a   Ohshima, Shiro ^a   Ishida, Tetsushi ^a   Kawase, Ichiro ^a   Mima, Toru ^a   Tabunoki, Youichiro ^a   Kobayashi, Hideyuki ^a   Maeda, Masahiro ^b   Uede, Toshimitsu ^c   Liaw, Lucy ^d   Kinoshita, Naokazu ^e   Saeki, Yukihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Maine Medical Center Research Institute   (United States)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ANTIBODY; OSTEOPONTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; GENE DELETION; GENE FUNCTION; IMMUNIZATION; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; IMMUNOGLOBULIN G; JOINTS; MALE; MICE; MICE, KNOCKOUT; OSTEOPONTIN; SIALOGLYCOPROTEINS; STIFLE;

EID: 10744226291     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20026     Document Type: Article

References (13)

1. Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 1999;7:103-13.
2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4.
3. Chabas D, Baranzini SE, Mitchell D, Bernard CCA, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-5.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
5. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, et al. Enhanced local production of osteopontin (OPN) in rheumatoid joints. J Rheumatol 2002;29:2061-7.
6. Ohshima S, Kobayashi H, Yamaguchi N, Nishioka K, Umeshita-Sasai M, Mima T, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 2002;46:1094-101.
7. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A 2002;99:4556-61.
8. Blom T, Franzen A, Heinegard D, Holmdahl R. Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease." Science 2003;299:1845.
9. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BLM. Altered wound healing in mice lacking a functional osteopontin gene (sppl). J Clin Invest 1998;101:1468-78.
10. Tada Y, Ho A, Koh DR, Mak TW. Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. J Immunol 1996;156:4520-6.
11. Kagari T, Doi H, Shimozato T. The importance of IL-1β and TNF-α, and noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002;169:1459-66.
12. Hom JT, Cole H, Estridge T, Gliszcynski VL. Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice. Clin Immunol Immunopathol, 1992;62:56-65.
13. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med, 2000;191:313-20.